We present the first demonstration of an electrochemically-active biomaterial probe for schizophrenia treatment monitoring, and its integration in lab-on-a-chip devices. The probe consists of the naturally derived polymer, chitosan, grafted with catechol to provide a redox cycling system. These modifica...
Testing is initially completed at one-week intervals but is expanded to two-week intervals at six months, and then four-week intervals at twelve months if lab results have been within an appropriate range. Monitoring parameters may change if there is any break in therapy. In Canada, the ...
Kim Vyas, R.C. Love, H.J. Wehring, K.M. Sullivan, S. Feldman, F. Liu, R.P. McMahon, R. Ghodssi, Development of a lab-on-a-chip biosensor for clozapine monitoring, 52nd Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, Florida, United States, 2013....
Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 2012;73:837–842. Article PubMed Google Scholar Drew, L. Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry 2013;21:335–337. Article PubMed...
Point-of-care haematological monitoring during treatment with clozapineMatthew AtkinsPhilip McGuireBhirundra BalgobinSophie WilliamsFatou CeesayNeville DesouzaPravinkumar PatelDavid Taylor
Point-of-care haematological monitoring during treatment with clozapineMatthew AtkinsPhilip McGuireBhirundra BalgobinSophie WilliamsFatou CeesayNeville DesouzaPravinkumar PatelDavid Taylor
The FDA has rigid treatment guidelines for hematologic monitoring for clozapine patients. If the white blood cell (WBC) count or absolute neutrophil count (ANC) falls below predetermined values, clozapine treatment must be held or discontinued. Diurnal and ethnic variations in complete blood count (...
Point-of-care haematological monitoring during treatment with clozapineMatthew AtkinsPhilip McGuireBhirundra BalgobinSophie WilliamsFatou CeesayNeville DesouzaPravinkumar PatelDavid Taylor
Point-of-care haematological monitoring during treatment with clozapineMatthew AtkinsPhilip McGuireBhirundra BalgobinSophie WilliamsFatou CeesayNeville DesouzaPravinkumar PatelDavid Taylor
Point-of-care haematological monitoring during treatment with clozapineMatthew AtkinsPhilip McGuireBhirundra BalgobinSophie WilliamsFatou CeesayNeville DesouzaPravinkumar PatelDavid Taylor